“Entering 2024 from a position of strength, we’re increasing both top and bottom-line financial guidance due to robust business trends and strong forward-looking product demand indicators. Additionally, we’ve identified new growth opportunities that we believe have the potential to approximately double currently provided peak revenue and earnings by the end of this decade,” said Adam Grossman, President and Chief Executive Officer of ADMA. “These growth opportunities, such as manufacturing yield enhancement and the commencement of pre-clinical development for our new S. pneumonia hyperimmune pipeline program, are expected to be capital-efficient and will not impact the upwardly revised 2024-2025 profitability guidance.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADMA:
- ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
- ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
- ADMA Biologics announces FDA approval of BIVIGAM in pediatric patient setting
- ADMA Biologics receives FDA approval for tenth plasma collection cent er
- ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD